Anagram Therapeutics develops orally delivered recombinant enzyme replacement therapies for rare malabsorption and nutrient metabolism disorders, such as exocrine pancreatic insufficiency and cystic fibrosis. Their lead product, ANG003, combines lipase, protease, and amylase in a stable, low‑pill‑count formulation that provides broad‑spectrum digestion support and is currently in Phase 2 trials. The platform leverages enzyme stabilization technology to create non‑porcine, clinically viable treatments that reduce dosing burden and improve supply reliability.
Funding
$28.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Malabsorption syndromes and nutrient metabolism disorders, such as exocrine pancreatic insufficiency and cystic fibrosis‑related enzyme deficiencies, prevent patients from properly digesting and absorbing essential nutrients. Existing treatments rely on pig‑derived pancreatic enzyme replacement therapies that require high pill burdens, have stability issues, and suffer from global shortages, leaving many patients inadequately treated or without any therapy.
Solution
Anagram Therapeutics develops orally delivered recombinant enzyme replacement therapies that are engineered for stability and immediate activity in the gastrointestinal tract. Their lead candidate, ANG003, combines lipase, protease, and amylase in a single broad‑spectrum formulation to address fat, protein, and carbohydrate malabsorption in a low‑pill‑count regimen. By using non‑porcine, recombinant enzymes, the platform aims to reduce treatment burden, improve safety, and provide a reliable supply chain. The company applies decades of gastrointestinal disease expertise and novel enzyme stabilization technologies to create a pipeline of similar orally delivered therapeutics for other rare malabsorption and metabolic disorders.
Target Audience
Primary customers are patients with rare, life‑threatening malabsorption disorders such as exocrine pancreatic insufficiency and cystic fibrosis, as well as the clinicians and specialty centers that prescribe enzyme replacement therapies.
Features
- Recombinant, non‑porcine enzyme cocktail (lipase, protease, amylase) formulated for oral delivery
- Engineered for gastric stability and rapid activation in the intestine to maximize nutrient digestion
- Low‑pill‑count dosing compared with traditional pig‑derived pancreatic enzyme replacement therapies
- Broad‑spectrum activity addresses multiple macronutrient deficiencies in a single product
- Pipeline of additional engineered enzymes targeting congenital and acquired malabsorption syndromes
- Clinical‑stage development with ANG003 currently in Phase 2 trials for cystic fibrosis‑related exocrine pancreatic insufficiency